CHEMOTHERAPY FOR PRIMARY HEPATIC MALIGNANCIES Maria Poulou, Eleni Makropoulou, Evangelos Repassos, Emanuel Xydakis, Maria Papadakou, Gerasimos Panagos.

Slides:

Advertisements

Similar presentations

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Advertisements

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.

Joint Hospital Surgical Grand Round 21 st July, 2012 RH.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Cholestatic liver diseases:

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)

Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Are there benefits from chemotherapy to early endometrial cancer

10 Minutes Talk 吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.

State of the Art: Gestational Trophoblastic Lesions Treatment beyond single agents Barry Hancock (Sheffield, UK) International Gynecologic Society Meeting.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

Malignant Pleural Effusion (M.P.E.)

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

IMPROVED OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SOFT-TISSUE OR BONE SARCOMAS WHO ACHIEVED A CLINICAL-BENEFIT RESPONSE WHEN TREATED WITH AP23573, A.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

Campbell’s & Literature review. Campbell 9 th & 10 th edition Cytoreductive nephrectomy  Palliation for: 1. Severe bleeding. 2. Pain. 3. Paraneoplastic.

Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,

INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

CLINICAL OUTCOME OF 251 PATIENTS WITH EXTRAHEPATIC METASTASIS AT INITIAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Randomized Phase III Study Of Gemcitabine

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Short-term outcome of neo-adjuvant chemotherapy

CCO Independent Conference Highlights

BIBF 1120 (Nintedanib) in platinum-resistant ovarian cancer:

Results of Definitive Radiotherapy in Anal Canal Carcinoma

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Intervista a Lucio Crinò

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

NAACCR/IACR Combined Annual Conference 2019

Presentation transcript:

CHEMOTHERAPY FOR PRIMARY HEPATIC MALIGNANCIES Maria Poulou, Eleni Makropoulou, Evangelos Repassos, Emanuel Xydakis, Maria Papadakou, Gerasimos Panagos Department of Medical Oncology Agii Anargiri Cancer Hospital of Kifisia Athens, Greece

The prognosis for stage IV primary tumors of the liver is poor and no surgical treatment is recommended Although there were initial encouraging reports of single-agent doxorubicin therapy for hepatocellular carcinoma in Uganda, subsequent studies have failed to confirm the early enthusiastic reports for this or any other single agent The consensus is that no single agent or combination of agents given systemically reproducibly leads to greater than 25% response rates or has any effect on survival

Based on review of published studies of chemotherapy, there is no consensus as to the best agent or regimen for unresectable or metastatic cholangiocarcinoma Due to the rarity of the disease, randomized studies have not been conducted In addition, a significant number of patients present with biliary obstruction and elevated levels on liver function tests, which severely curtails the ability to administer chemotherapy

Patient population Seventeen patients with primary hepatic malignancies studied retrospectively for their response to chemotherapy Histology was hepatocellular carcinoma in 11 and cholangiocarcima in 6 Disease stage was IVA in 10 and IVB in 7 A1-fetoprotein was high in 6 cases while CA 19-9 in 7 Male:female ratio was 12:5 Median age was 63 (42 to 75, average 61).

Treatment All patients received at least 1 cycle of chemotherapy Twelve patients received doxorubicin based chemotherapy as first line treatment while 5 cisplatin based

Characteristics, treatments and response to treatment of the hepatocellular carcinoma patients Male/Female8/3 ECOG P.S. 0-2/>23/8 Average age (range)63 (48–75) Stage IVA/VIB6/5 Increased A1Fetoprotein/CA 19-96/2 L.Dox/Dox/L.Dox+FU+Tam/cPla+FU+L/cPla+Ctx7/1/1/1/1 CR/SD+TMd/SD/SD+TMi/PD/PD+TMi1/2/1/1/2/4 2nd line of treatment3 3rd line of treatment/4th line of treatment2/1 Average Overall Survival (range)11 (1–48)

Characteristics, treatments and response to treatment of the cholangiocarcinoma patients Male/Female4/24/2 ECOG P.S. 0-2/>23/3 Average age (range)58 (42–68) Stage IVA/VIB4/2 Increased CA L.Dox/cPla+FU+L/cPla+FU+L+VP3/1/2 ObjR+TMd/TMd/PD1/1/4 2nd line of treatment4 3rd line of treatment/4th line of treatment1/1 Average Overall Survival (range)14 (5–21)

Four patients are still alive and continuing treatment Median overall survival is 11 months (1 to 48+, standard deviation 9.8) Stage IVA and quick tumor marker regression after treatment are good prognostic factors Histology and histologic grading do not seem to possess prognostic significance Both doxorubicin and cisplatin based chemotherapy give objective responses while it seems unlikely for cross resistance to exist